Journal
BIOENGINEERING-BASEL
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/bioengineering9040166
Keywords
cancer; 3D cancer models; point-of-care modelling tool; gap analysis; commercialization
Funding
- FROnTHERA [NORTE-01-0145-FEDER-000023]
- European Union Framework Programme for Research and Innovation Horizon 2020 [668983-FoReCaST]
- FCT under the doctoral program in Tissue Engineering, Regenerative Medicine and Stem Cells [PD/BD/143050/2018]
- FCT through the BREAST-IT project [PTDC/BTM-ORG/28168/2017]
- Fundação para a Ciência e a Tecnologia [PD/BD/143050/2018] Funding Source: FCT
Ask authors/readers for more resources
In vitro cancer models are considered as efficient screening platforms for potential therapies and personalized treatments. However, the low success rate of cancer therapeutics calls for critical evaluation of current preclinical platforms to accelerate the development and commercialization of in vitro cancer models.
In vitro cancer models are envisioned as high-throughput screening platforms for potential new therapeutic discovery and/or validation. They also serve as tools to achieve personalized treatment strategies or real-time monitoring of disease propagation, providing effective treatments to patients. To battle the fatality of metastatic cancers, the development and commercialization of predictive and robust preclinical in vitro cancer models are of urgent need. In the past decades, the translation of cancer research from 2D to 3D platforms and the development of diverse in vitro cancer models have been well elaborated in an enormous number of reviews. However, the meagre clinical success rate of cancer therapeutics urges the critical introspection of currently available preclinical platforms, including patents, to hasten the development of precision medicine and commercialization of in vitro cancer models. Hence, the present article critically reflects the difficulty of translating cancer therapeutics from discovery to adoption and commercialization in the light of in vitro cancer models as predictive tools. The state of the art of in vitro cancer models is discussed first, followed by identifying the limitations of bench-to-bedside transition. This review tries to establish compatibility between the current findings and obstacles and indicates future directions to accelerate the market penetration, considering the niche market.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available